|RMD -- USA Stock|| |
USD 108.97 0.36 0.33%
Mr. Don Darkin is President innovation operations of Resmed Inc. Previously Mr. Darkin was president sleepdisordered breathing strategic business unit a position he began in May 2011 and senior vice president strategic business unit patient interfaces from July 2007 to May 2011. Before these positions Mr. Darkin held several senior roles within ResMed. He joined ResMed in August 1999 as vice president product development. In May 2005 he became director of operations in France for ventilation and subsequently served as vice president business divisions and senior vice president global product development. Before working at ResMed Mr. Darkin served as vice president of operations for Ambri Pty Ltd. Australia and vice president product development for Telectronics Medical Systems Australia and US. Mr. Darkin is identified as an inventor or coinventor on over 80 granted patents worldwide. Mr. Darkin was educated in the UK in mechanical engineering and has further professional management training from University of New South Wales and Massachusetts Institute of Technology.
Age: 61 President Since 2014
Don Darkin Latest Insider Activity
The company has Return on Asset of 9.58 %
which means that on every $100 spent on asset it made $9.58 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE)
of 15.68 %
implying that it generated $15.68 on every 100 dollars invested.
The company has 810 M in debt with debt to equity (D/E) ratio of 39.1 . This implies that the company may be unable to create cash to meet all of its financial commitments. ResMed has Current Ratio of 3.41 demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California. ResMed operates under Medical Instruments Supplies classification in USA and traded on BATS Exchange. It employs 6000 people.ResMed (RMD) is traded on BATS Exchange in USA. It is located in CALIFORNIA U.S.A and employs 6,000 people. ResMed is listed under Medical Equipment category by Fama And French industry classification.
ResMed Leadership Team
|John Wareham, Independent Director|
|Ronald Taylor, Lead Independent Director|
|Rob Douglas, President COO|
|Christopher Roberts, Independent Director|
|Gary Pace, Independent Director|
|Chris Roberts, Independent Director|
|Robert Douglas, Pres and COO|
|Agnes Lee, Senior Director - Investor Relations|
|Carol Burt, Independent Director|
|Rich Sulpizio, Independent Director|
|Peter Farrell, Non-Executive Chairman of the Board|
|Jim Hollingshead, President - Americas|
|Brett Sandercock, CFO and Principal Accounting Officer|
|Ron Taylor, Lead Independent Director|
|Don Darkin, President - Sleep-disordered Breathing Strategic Business Unit|
|Jack Wareham, Independent Director|
|Anne Reiser, President Europe|
|Karen Drexler, Director|
|Raj Sodhi, President ? Software as a Service (SaaS) Business and CTO|
|David Pendarvis, Chief Admin. Officer, Global General Counsel and Secretary|
|Richard Sulpizio, Independent Director|
|Michael Farrell, CEO and Director|
|Richard McHale, President ? Respiratory Care|
|Donald Darkin, President ? innovation & operations|
Stock Performance Indicators
Greater number of Macroaxis users are at this time bullish on ResMed. What is your perspective on investing in ResMed? Are you bullish or bearish?
Currently Active Assets on Macroaxis
Additionally take a look at Your Equity Center
. Please also try Fundamentals Matrix
module to view fundamentals matrix and analyze how accounts are interrelated and interconnected with each other.